Aura Biosciences financials
$6.150.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$48.1M | -$34.9M | -$27.2M | -$27.9M | -$28.6M | -$29.0M | -$27.8M | -$23.2M | -$22.8M | -$22.3M | -$24.8M | -$20.5M |
| Net income | -$45.6M | -$33.7M | -$25.6M | -$26.1M | -$27.0M | -$27.5M | -$25.8M | -$21.0M | -$20.3M | -$19.7M | -$22.1M | -$18.5M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.48 | $-0.50 | $-0.38 | $-0.40 | $-0.47 | $-0.55 | $-0.52 | $-0.42 | $-0.41 | $-0.40 | $-0.50 | $-0.48 |
| EBITDA | -$47.8M | -$34.6M | -$27.0M | -$27.6M | -$28.3M | -$28.7M | -$27.5M | -$22.9M | -$22.4M | -$22.0M | -$24.5M | -$20.1M |
| Operating cash flow | -$32.5M | -$29.9M | -$20.5M | -$20.1M | -$20.8M | -$23.4M | -$24.0M | -$15.3M | -$16.1M | -$24.5M | -$17.4M | -$15.4M |
| Free cash flow | -$32.5M | -$30.0M | -$20.6M | -$20.2M | -$20.8M | -$23.5M | -$24.3M | -$15.6M | -$16.7M | -$24.5M | -$17.7M | -$15.5M |
| Diluted shares | 94.9M | 67.4M | 67.3M | 65.9M | 58.0M | 50.1M | 49.9M | 49.7M | 49.5M | 49.5M | 44.7M | 38.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $67.8M | $84.8M | $59.5M | $47.6M | $107.4M | $38.2M |
| Short-term investments | $256.0M | $29.9M | $84.7M | $114.3M | $69.9M | $89.8M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $348.1M | $137.7M | $169.4M | $190.0M | $204.4M | $155.4M |
| Total liabilities | $32.9M | $30.4M | $32.5M | $33.4M | $29.8M | $27.4M |
| Shareholders' equity | $315.3M | $107.2M | $136.9M | $156.7M | $174.6M | $128.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology